


# California Department of Public Health Immunization Updates for Providers

Friday, January 12, 2024

9:00AM – 10:30AM

# Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, "Chat"



# Housekeeping

## Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

## Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#)



To be added to the CDPH email messaging listserv for providers, please email your request to [billiedawn.greenblatt@cdph.ca.gov](mailto:billiedawn.greenblatt@cdph.ca.gov)

If you have post-webinar-related questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov)

# Agenda: Friday, January 12, 2024

No.	Item	Speaker(s)	Time (AM)
1	Welcome and Announcements	Leslie Amani (CDPH)	9:00 – 9:05
2	COVID-19 Vaccine Administration Data	Hailey Maeda (CDPH)	9:05 – 9:10
3	COVID-19 Therapeutics Clinical Update	Jessica deJarnette, MD (CDPH)	9:10 – 9:20
4	Clinical Updates	Jennie Chen, MD (CDPH)	9:20 – 9:25
5	COVID-19 Vaccine Storage and Handling	Kelley Leung, RN (CDPH)	9:25 – 9:30
6	Vaccines for Children (VFC) Update	Christina Sapad (CDPH)	9:30 – 9:40
7	Vaccine Management	Josh Pocus (My Turn) and Claudia Aguiluz (myCAvax)	9:40 – 9:50
8	Resources and Q&A	Leslie Amani (CDPH)	9:50 – 10:30

**Thank you!**



# Announcements


Leslie Amani, CDPH



# January Holiday

Dr. Martin Luther King, Jr., Day  
Monday, January 15, 2024

In observance, CDPH and the  
Provider Call Center will be closed.



### About the Training Series:

- **What:** Building Impact: Your HPI Toolkit Training Series (6 sessions). Scroll down below and see attached flyer for details on each session.
- **When:** Sessions run January 2024 to June 2024, with each session scheduled for 60 to 90 minutes.
- **Where:** Virtual - Zoom. Register using the links down below.

## INTRO TO BUILDING IMPACT: YOUR HPI TOOLKIT

[Register for January 23, 2024, 1:00 to 2:00 PM](#)

Uncover the power of the NEW California Healthy Places Index® 3.0 in our introductory session. Get oriented to our training series and learn how HPI is used to impact community health across the state.

If you have any questions about this training series, please contact Helen Dowling at [hdowling@phi.org](mailto:hdowling@phi.org).

### Building Impact: Your HPI Toolkit

Unlock the full potential of the California Healthy Places Index® (HPI) in this comprehensive training journey for all skill levels.



You're invited to our *Building Impact* HPI training series – a dynamic learning journey designed for all audiences, whether you're a program specialist or a research scientist. Each session, scheduled from January to June, promises a hands-on experience with engaging activities, open discussions, and dedicated Q&A sessions.

With a practical focus and clear use cases tailored to your work, **feel free to register for one or join us for the entire series**, where each session builds upon the last, introducing

new skills and concepts to empower you in positively impacting community health across the state.

#### 1. INTRO TO BUILDING IMPACT: YOUR HPI TOOLKIT

[Register for January 23rd 1:00 – 2:00 PM](#)

Uncover the power of the NEW California Healthy Places Index® 3.0 in our introductory session. Get oriented to our training series and learn how HPI is used to impact community health across the state.

#### 2. HPI 101: A COMPASS FOR NAVIGATING PRIORITY COMMUNITIES

[Register for February 8th 1:00 – 2:30 PM](#)

Dive into the essentials of HPI, exploring its core principles and NEW data. Learn how to identify and characterize priority communities and equip yourself with the skills to accurately interpret HPI data.

#### 3. EQUITY OPPORTUNITIES UNVEILED: INFORMING PROGRAM DESIGN WITH HPI

[Register for March 7th 1:00 – 2:30 PM](#)

Discover opportunities to advance health equity as we explore how HPI can inform program design. Learn practical ways to leverage HPI data in shaping interventions that truly address the needs of diverse communities.

#### 4. ENGAGE, EMPOWER, ENRICH: STORYTELLING WITH HPI

[Register for April 11th 1:00 – 2:30 PM](#)

Embark on a journey of engagement strategies with HPI. Leverage the power of storytelling with HPI data to amplify community voices and foster connections that drive positive health outcomes.

#### 5. YOUR DATA & HPI

[Register for May 9th 1:00 – 2:30 PM](#)

Navigate the ins and outs of HPI data management in this session, including uploading your data to the HPI map and downloading HPI data through our API. Learn best practices to get the most out of using your data with HPI.

#### 6. HEALTH EQUITY METRICS & RESEARCH APPLICATIONS WITH HPI


[Register for June 4th 1 – 2:30 PM](#)

Explore the intersection of health equity metrics and research applications with HPI. Gain valuable insights into utilizing HPI data for impactful research that contributes to the broader goal of creating healthier and more equitable communities.

# 2024 Vaccines for Children (VFC) Annual Recertification


## Multi-page letter includes:


- Background
- Process
- Requirements
- Enclosures



The image shows the front page of a letter from the California Department of Public Health regarding the 2024 Vaccines for Children (VFC) Annual Recertification. The letter is dated December 20, 2023, with reference number IZB-FY-23-24-11. It is addressed to VFC providers and signed by Robert Schechter, M.D., Chief of the Center for Infectious Diseases. The subject is the 2024 Annual VFC Recertification. A key takeaway box highlights that providers must complete all steps by January 31, 2024, and that failure to do so will result in suspension of vaccine ordering. The letter also provides background on the VFC program and instructions to submit the recertification form by January 31, 2024, via the MyVFCVaccines account. Contact information for the VFC program is provided at the bottom, including the address at 850 Marina Bay Parkway, Richmond, CA, and the website www.eziz.org.


State of California—Health and Human Services Agency  
California Department of Public Health

  
TOMÁS J. ARAGÓN, M.D., Dr.P.H.  
Director and State Public Health Officer

  
GAVIN NEWSOM  
Governor

December 20, 2023 IZB-FY-23-24-11

TO: California Vaccines for Children (VFC) Providers

FROM: Robert Schechter, M.D., Chief   
Center for Infectious Diseases  
Division of Communicable Disease Control, Immunization Branch

SUBJECT: 2024 Annual VFC Recertification

**Key takeaways from this letter:**

- ✓ By January 31, 2024, please complete all steps in the VFC Recertification process, including completing the required lessons on EZIZ.
- ✓ Not completing VFC Recertification will result in suspension of vaccine ordering and eventual termination from the VFC Program.

**BACKGROUND**


Thank you for your continued participation in the Vaccines for Children (VFC) Program, which ensures access to necessary immunizations for vulnerable children. Annual Recertification and Training is a federal requirement for public and private providers to continue receiving publicly purchased vaccines in the VFC Program. All providers that enrolled prior to December 2023 must complete 2024 VFC Recertification. Not completing 2024 VFC Recertification process will result in suspension of vaccine ordering privileges and eventual account termination from the VFC Program.

Through Recertification, providers agree to comply with VFC Program participation requirements, update practice information, and provide updated estimates of all VFC-eligible and privately insured children who will be immunized in the coming year. The VFC Program then verifies that the practice is eligible for continued enrollment and has a current and valid California medical license to prescribe and administer vaccines.

**SUBMIT 2024 VFC RECERTIFICATION BY JANUARY 31, 2024**

The 2024 VFC Recertification form is now available on your [MyVFCVaccines](#) account. Submit your completed Recertification by **Wednesday, January 31, 2024**. Once verified, recertification will be valid through 2024.

California Vaccines for Children (VFC) Program  
850 Marina Bay Parkway, Bldg. P, 2<sup>nd</sup> Floor, Richmond, CA 94804  
(877) 243-8832 • FAX (877) 329-9832 • Internet address: [www.eziz.org](http://www.eziz.org)





# EZIZ Storage and Handling

## Covers:

- Vaccine Storage Units
- Types and Grades
- Refrigerator and Freezer Specifications
- Configuring Units
- More details

The screenshot displays the EZIZ website interface. At the top left is the EZIZ logo featuring a family icon. To the right is a search bar with the text "ENHANCED BY Google" and a magnifying glass icon. Below the search bar is the tagline "A one-stop shop for immunization training and resources." The main navigation menu on the left includes: Home, Vaccine Programs, Vaccine Management, Storage Units, Temperature Monitoring, Training & Webinars, Clinic Resources, and Patient Resources. The "Storage & Handling" section is highlighted in blue. It contains the following content:

- Vaccine Storage Units**

Participating providers agree to store all VFC-supplied vaccines in vaccine refrigerators and freezers that meet California VFC Program requirements. Adherence to storage and handling requirements is certified as part of annual provider recertification and during both routine and unannounced site visits conducted by VFC Field Representatives.

The California VFC Program does not endorse or recommend specific products. Providers may purchase any vaccine storage units that meet California VFC Program requirements outlined below.

If you are unclear about vaccine storage unit requirements, contact your VFC Field Representative prior to making a purchase.
- Types and Grades**
- Refrigerator Specifications**
- Acceptable Vaccine Refrigerators**
- Freezer Specifications**
- Acceptable Vaccine Freezers**
- Unacceptable Vaccine Storage Units**
- Purchasing and Placement Considerations**
- Configuring Units for Vaccine Storage**

**Additional Resources:**

- Storage & Handling Job Aids
- Digital Data Loggers
- Monitoring Storage Unit Temperatures
- Vaccine Management

On the right side, there is a "Storage & Handling Resources" section with a list of links:

- ▶ Vaccine Storage Units
- ▶ Storage & Handling Job Aids
- ▶ Monitoring Storage Unit Temperatures
- ▶ Digital Data Logger Requirements
  - ▶ DDL Feature Comparison Guide
- ▶ Questions for Vendors
- ▶ DDL Calibration Testing | FAQs
- ▶ How to Get Devices Calibrated
- ▶ Accredited Labs
- ▶ Power Shut-Offs

# EZIZ Digital Data Loggers (DDLs)

## DDLs information includes:

- Specifications
- Temperature Monitoring
- Purchasing Considerations

**EZIZ** ENHANCED BY Google

**A one-stop shop for immunization training and resources.**

- Home
- Vaccine Programs
- Vaccine Management
- Storage Units
- Temperature Monitoring
- Training & Webinars
- Clinic Resources
- Patient Resources

**Digital Data Loggers**

Digital data loggers (DDLs), also called "continuous temperature monitoring devices" or just "data loggers," continuously read and record temperatures to provide an accurate report of vaccine temperatures over time. DDLs also alert clinic staff when temperatures are out of the recommended range via visual, audible and/or electronic notifications. DDLs read and record temperatures at set time intervals and store data in an internal memory. Clinic staff can download and save the data as an electronic file on a computer and analyze vaccine storage unit temperature trends over time.

All VFC providers must use a VFC-compliant DDL in every refrigerator and freezer storing VFC-supplied vaccines. Practices also must have at least one battery operated backup DDL to use when a primary device is being calibrated, during emergency vaccine transport, or if a primary device fails. Depending on the size of the practice, additional devices may be needed. Every device must have a valid and current certificate of calibration on file.

Because monitoring devices experience a "drift" over time that affects their accuracy, DDLs must be certified for accuracy every two years, or three years when manufacturers recommend a period longer than two years. Calibrate primary and back-up devices on different schedules to ensure all refrigerators and freezers are always equipped with data loggers with a valid and current certificate of calibrations. VFC also encourages calendaring calibration testing so that it is done at least 2-3 months prior to a DDL's expiration date. DDL expiration dates should be documented on the clinic's Vaccine Management Plan.

In preparation for the annual VFC Program Recertification process, clinics are strongly encouraged to verify all their DDLs are calibrated and that the certificates of calibration are current.

**Importance and Use of Data Loggers**

Data loggers

- monitor vaccine temperatures continuously—even when the practice is closed,
- may have alert capabilities to notify clinic staff of temperature excursions during non-business hours,
- determine how long vaccines have been exposed to out-of-range temperatures,
- prevent unnecessary vaccine losses when excursion time frames cannot be precisely determined, and
- show how a storage unit's temperature increases and decreases over time.

**+ Data Logger Specifications**

**+ Unacceptable Temperature Monitoring Devices**

**+ Purchasing Considerations**

**+ When You're Ready to Purchase**

**Purchase and Maintenance Resources:**

**Storage & Handling Resources**

- ▶ Vaccine Storage Units
- ▶ Storage & Handling Job Aids
- ▶ Monitoring Storage Unit Temperatures
- ▶ Digital Data Logger Requirements
  - ▶ DDL Feature Comparison Guide
  - ▶ Questions for Vendors
  - ▶ DDL Calibration Testing | FAQs
  - ▶ How to Get Devices Calibrated
  - ▶ Accredited Labs
  - ▶ Power Shut-Offs

## Suggested Message: Cold and Flu Season is Still Underway, Take Precautions

Cold and flu season is still underway, and hospitalizations for COVID-19 and flu are on the rise. Share [messages on social media](#) reminding Californians to take precautions, like wearing a mask in crowded indoor spaces, to reduce the spread of respiratory viruses. It's also not too late to get flu and COVID-19 vaccines - and you can get both vaccines at the same time. Schedule a vaccine appointment with a health care provider or at [MyTurn.ca.gov](https://www.myturn.ca.gov).

Learn more:

- [Respiratory Viruses webpage.](#)
- [Flu & COVID-19 Vaccines Communications Toolkit.](#)
- [Respiratory Virus Prevention Communications Toolkit.](#)
- [RSV Vaccine Communications Toolkit.](#)






## New Data Briefs: COVID-19's Impact on Pregnant People and Families

Did you know that more than half of all California families with new babies lost income due to the COVID-19 pandemic? CDPH recently released a [new data brief series](#) examining the well-being of Californians who gave birth early in the COVID-19 pandemic. The data briefs examine the following topics as related to the COVID-19 pandemic:


- Food Insecurity and Housing Instability
- Income Loss, Job Loss, and Childcare Problems
- Mental Health During and After Pregnancy
- Visit [go.cdph.ca.gov/MIHACOV19](https://go.cdph.ca.gov/MIHACOV19) to read the findings.



Early in the COVID-19 pandemic,

**MORE  
THAN HALF**

of California families with a new baby lost income due to the pandemic.








## Social Media Spotlight: CDPH's Top Posts of 2023

CDPH Communications took a walk down memory lane to revisit CDPH's top 10 social media posts of 2023. [Take a look at the top 10 CDPH posts](#) that got people talking in 2023.

[Sign up for this newsletter](#)  
Sign up for [CDPH News Releases](#)  
Sign up for [CDPH Policy Alerts](#)  
CDPH [Office of Communications Toolkits](#)  
[CDPH News Release](#) archive



# COVID-19 Vaccine Administration Data

Hailey Maeda, CDPH


# COVID-19 Vaccine Administration Summary

as of January 9, 2024

**94,902,259**

Total Doses Administered:


Daily Doses Administered: **Statewide**



**4,916,543**

Total Up-to-Date\* Recipients:

Percent of Population Who Are Up-to-Date



\*Has received a dose of the Updated 2023-2024 vaccine



[Public Dashboard Link](#)  
[LHJ Dashboard Link](#)

[CDC - Updated 2023-2024 Formula mRNA Vaccine](#)

# Trends in COVID-19 Vaccine Administration

as of January 9, 2024

## Most Recent Eligibility Groups

Updated 2023-2024 vaccine for 6 months and older


FDA NEWS RELEASE

## FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

[Share](#)
[Tweet](#)
[LinkedIn](#)
[Email](#)
[Print](#)

For Immediate Release: September 11, 2023

Doses Administered by Age Group, Past 4 Weeks



# Up-to-Date COVID-19 Vaccination Status

## Race/Ethnicity\* and Age


as of January 9, 2024

### By race and age:

Highest uptake among NHPI, White, and AIAN

Uptake above statewide average in all 65+ race/ethnicity groups

Percent of 65+ Population Who Are Up-to-Date by Age and Race/Ethnicity



\*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination


# Updated 2023-2024 COVID-19 Vaccine Doses

## Providers and Age

as of January 9, 2024

Majority of Pediatric doses are administered by Healthcare providers while Adults receive most of their doses via Pharmacy

Updated 2023-2024 Doses by Providers and Recipient Age Group



# COVID-19 Vaccine Data Summary

as of January 9, 2024

## Key Metrics

<b>94.9 million</b> doses administered	<b>+143K</b> doses administered
<b>12.3%</b> Statewide who are Up-to-Date	<b>4.9 million</b> Up-to-Date recipients
<b>31.4%</b> 65+ population Up-to-Date	<b>2.0 million</b> 65+ Up-to-date recipients

## System Notes

- Public dashboard Up-to-Date status now **includes** the Updated 2023-2024 guidelines
- Email [cdphvaccinatedatateam@cdph.ca.gov](mailto:cdphvaccinatedatateam@cdph.ca.gov) for questions and comments

# COVID-19 Therapeutics Clinical Update

Jessica deJarnette, MD, CDPH



## SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals

Dallas J. Smith, PharmD<sup>1,2</sup>; Anastasia Lambrou, PhD<sup>1,2</sup>; Pragna Patel, MD<sup>3</sup>

- CDC reviewed SARS-CoV-2 rebound studies published during February 1, 2020– November 29, 2023.
- 7 out of 23 studies met inclusion criteria, 1 RCT and 6 observational studies
- In four studies, including the randomized trial, no statistically significant difference in rebound rates was identified among persons receiving treatment and those not receiving treatment.
- Depending on the definition used, the prevalence of rebound varied.
- No hospitalizations or deaths were reported among outpatients who experienced rebound, because COVID-19 signs and symptoms were mild.

## SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals

Dallas J. Smith, PharmD<sup>1,2</sup>; Anastasia Lambrou, PhD<sup>1,2</sup>; Pragna Patel, MD<sup>3</sup>

- 3 of the observational studies found a higher frequency of rebound (10-14%) in treated persons, two of these studies focused exclusively on elderly persons (>65y) and those with chronic lymphocytic leukemia (CLL).
- Among 22 patients (from three studies) with available virologic data and who received treatment, median time to negative test results was 6 days after initial positive test result. Median time to viral rebound was 9 days after diagnosis, and to resolution was 16 days into the viral illness.
- Risk factors for rebound appear to be similar to risk for severe disease, but further studies are needed to understand whether persons with certain characteristics or underlying medical conditions are predisposed to experiencing rebound.
- Study highlights theory that rebound may be due to resumption of viral replication after completion of treatment because of delayed viral clearance.


## SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals

Dallas J. Smith, PharmD<sup>1,2</sup>; Anastasia Lambrou, PhD<sup>1,2</sup>; Pragna Patel, MD<sup>3</sup>

- Comment made that rebound does not likely represent viral resistance, this was not demonstrated in studies that had viral replication data but more studies are needed.
- Several limitations including: 1) no consensus definition of rebound; 2) difficulty in verifying whether antiviral treatment courses were completed and whether vaccination status and previous infection were documented accurately in observational studies; 3) ascertainment bias is also possible given that persons receiving antiviral treatment are closely followed, and more likely to report recurrent symptoms, which would explain the early case reports being associated with nirmatrelvir/ritonavir; etc.
- **Takeaway: Rebound still should not deter clinicians from prescribing antiviral medications for COVID-19 because if it does occur symptoms are mild, resolve quickly, and are not associated with adverse outcomes such as severe disease or death**

# UCSF Long Covid Study

- Studied group of vaccinated persons from the UCSF Covid-19 Citizen Science study who had reported their first positive test for COVID-19 between March and August of 2022 and who were not hospitalized
- 1611 participants, 66% female, median age 55 years
- Some of these participants reported taking oral Paxlovid treatment during the acute phase of their COVID infection, while others did not. In December of 2022, they were invited to answer a follow-up survey with questions about long COVID, COVID rebound symptoms and how long they continued to test positive.
- About 16% of those treated with Paxlovid had long COVID symptoms compared to 14% of those who were not treated.
- Among individuals who experienced symptomatic improvement during Paxlovid treatment, 21% reported rebound symptoms. And among those with rebound, 10.8% reported one or more long COVID symptoms. For those who did not rebound, 8.3% reported at least one long COVID symptom.



# UCSF Long COVID Study

- For participants who repeated antigen testing after testing negative and completing treatment, 25.7% reported rebound test positivity. In total, 26.1% reported rebound symptoms or test positivity.
- Many limitations of this study, including self-reporting of symptoms by patients, definition of "first-time infection" etc.
- Still no consensus of what "Long COVID" is—sequelae of severe disease vs. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)?
- Does not refute studies that show a potential decrease in risk of Long COVID signs and symptoms (sxs) among patients who take antiviral medications

# Clinical Update

Jennie Chen, MD, CDPH





January 5, 2024

## Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season

On October 23, 2023, the Centers for Disease Control and Prevention (CDC) issued Health Alert Network (HAN) [Health Advisory 499](#) to provide guidance for prioritization of nirsevimab given limited supply. Nirsevimab (Beyfortus, Sanofi and AstraZeneca) is a long-acting monoclonal antibody immunization recommended for preventing RSV-associated lower respiratory tract disease in young children. Given the recent increase in nirsevimab supply and the [manufacturers' plan to release an additional 230,000 doses in January](#), CDC advises healthcare providers to return to recommendations put forward by CDC and the [Advisory Committee on Immunization Practices \(ACIP\)](#) on use of nirsevimab in young children. **Infants and children recommended to receive nirsevimab should be immunized as quickly as possible.** Healthcare providers should not reserve nirsevimab doses for infants born later in the season when RSV circulation and risk for exposure to RSV may be lower. RSV activity remains elevated nationwide and is continuing to increase in many parts of the country, though decreased activity has been observed in the Southeast.

January 5, 2024: CDC updated guidance advises healthcare providers to return to recommendations put forward by CDC and the [Advisory Committee on Immunization Practices \(ACIP\)](#) on use of nirsevimab in young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible.

# Limited Opportunities Remain to Prevent Severe RSV - Order, Use, Reorder Remaining Supplies of Nirsevimab ASAP!






## VFC Program:

- 50 mg and 100 mg doses of nirsevimab available now!

## Private market

- Check with distributor

### Optimizing RSV Protection for Infants with Limited Supply of Nirsevimab (Beyfortus™)<sup>1</sup> — Update January 2024



**Prenatal Vaccination**  
Administer prenatal RSV vaccine (ABRYOVO™, Pfizer) during 32-36 weeks' gestation, September through January.

- Prenatal vaccination may be the best and only option while RSV immunization for infants (nirsevimab) is in short supply.
- Most infants born to vaccinated birth parents will not need nirsevimab.

**Nirsevimab 50mg** for infants < 5kg and < 8 months without prenatal vaccination<sup>2</sup>

- Administer:
  - Now—infants born prior to October.
  - Within the first week of life—infants born during RSV season.

**Nirsevimab 100mg** for infants ≥ 5kg and < 8 months without prenatal vaccination<sup>2</sup>

- For palivizumab-eligible children, follow [AAP palivizumab recommendations](#) when nirsevimab is not available.

**Nirsevimab 200mg (two 100mg doses)** for children 8 – 19 months

- For palivizumab-eligible children, follow [AAP palivizumab recommendations](#) when nirsevimab is not available.

**RSV Season is here now!**  
Use and reorder remaining nirsevimab supplies promptly to protect infants and toddlers.

**Encourage other preventative measures including:**

- [Breastfeeding](#) to decrease the risk of severe RSV and hospitalization among infants
- Recommend everyone around infants are up to date on vaccines including flu, COVID-19, Tdap, and RSV for adults 60 years and older
- Wash hands
- Cover coughs and sneezes
- Clean frequently touched surfaces
- Sick persons should stay away from infants
- Limit number of visitors for infants

**Footnotes:**  
<sup>1</sup>[Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus \(RSV\) during the 2023–2024 Respiratory Virus Season](#)  
<sup>2</sup>Infants <8 months entering their first RSV season should receive immunization if birth parent's prenatal vaccination status is: unvaccinated, unknown, or vaccinated <14 days before birth.

California Department of Public Health, Immunization Branch IMM-1496 (1/24)



# Nirsevimab Resources

**EZIZ**  
A one-stop shop for immunization training and resources.

ENHANCED BY Google

**Home**  
**Vaccine Programs**  
**Vaccine Management**  
**Storage Units**  
**Temperature Monitoring**  
**Training & Webinars**  
**Clinic Resources**  
**Patient Resources**

**Contact VFC**  
Phone: (877) 243-8832  
Hours:  
Mon-Thurs, 9AM-4:30PM  
Friday, 9AM-4PM  
Send us an email  
Fax: (877) 329-9832

▶ VFC Field Representatives  
▶ Find VFC providers  
▶ Sign up for EZIZ emails  
▶ Frequently Asked Questions

**RSV**

## RSV Immunization Resources

### General Information for Providers

- RSV Immunization Information (CDC)
- RSV Immunization FAQs
- Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023-2024 Respiratory Virus Season
- RSV Trends in the United States (CDC)
- VFC Enrollment Checklist for Birthing/Pediatric Hospitals

### Infants and Children

- Optimizing RSV Protection for Infants with Limited Supply of Nirsevimab Infographic
- Nirsevimab Standing Orders (IAC)
- Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers
- Nirsevimab Guidance (CDC)
- Clinical Guidance to Prevent RSV Disease in Infants Webinar (CDC)
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
- Template Parent Portal and Robocall Messages for Infant RSV Immunization
- ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease (8/15/23)
- Nirsevimab Frequently Asked Questions (AAP)
- Beyfortus (Nirsevimab) Product Insert (FDA)
- CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth (Press Release)

## Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers

Nirsevimab should be given before the start of RSV season (usually October-March). The dosage depends on age, weight, and health condition. View [CDC's RSV page](#) for web version and additional guidance.

### All Infants <8 Months Entering 1st RSV Season

without prenatal vaccination during 32-36 weeks gestational age\*

**If born October-March**  
1 dose in <1 week of birth

**If born April-September**  
1 dose in October/November

Weight <5kg

Nirsevimab  
50mg

OR

Weight ≥5kg

Nirsevimab  
100mg

or as soon as possible during the RSV season

### High-Risk Children 8-19 Months Entering 2nd RSV Season

200mg dose  
before RSV season

Nirsevimab\*\*  
100mg

+

Nirsevimab\*\*  
100mg

or as soon as possible during the RSV season

(Two 100mg syringes, same day, different sites, regardless of weight)

#### High-risk conditions include:

- **Chronic lung disease of prematurity that required medical support** (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the RSV season.
- **Cystic fibrosis with either:**
  1. Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the 1st year if life or abnormalities on chest imaging that persist when stable OR
  2. Weight-for-length <10th percentile
- **Severe immunocompromise**
- **American Indian or Alaskan Native children**



\* In limited situations, an infant may be recommended to receive RSV immunization after prenatal vaccination.


\*\* If nirsevimab is unavailable and the child is eligible to receive palivizumab, then palivizumab should be administered. If < 5 doses of palivizumab are administered and nirsevimab becomes available, the child should receive 1 dose of nirsevimab.

# COVID-19 Vaccine Storage and Handling

Kelley Leung, RN, CDPH

# Refrigerated Pfizer Comirnaty

- Pfizer 12+ years (Comirnaty) now comes in glass, prefilled syringes (PFS).
- **MUST BE STORED BETWEEN 2°C and 8°C (36°F and 46°F).** Do NOT store at ultra-cold or standard freezer temperatures.
- Can be used through the expiration date printed on the carton or syringe, up to six months from date of manufacture
- Orders are shipped at refrigerated temperatures.
- There is no change to the shipping, storage, or handling of any other Pfizer presentation.



# Vaccines for Children (VFC)

Christina Sapad, CDPH

# VFC Beyfortus™ Supply Update


- Additional allocations of the 100mg Beyfortus™ have been received from CDC this week!
- All VFC providers may order 50mg and 100 mg doses of nirsevimab (Beyfortus™) via supplemental orders
- Current limits and eligibility are subject to change based on supply.

## Respiratory Syncytial Virus Surveillance

### RSV Detections from Clinical Sentinel Laboratories

The overall percentage of RSV detections in clinical sentinel laboratories during Week 52 was 8.6% compared to 9.1% during Week 51 ([Figure 12](#)).

Figure 12. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2018–2024 Season to Date



Note: Data have been shifted so that Week 1 aligns across seasons.

# ABRYSVO™ Available for VFC Ordering this month!

- RSV vaccine ABRYSVO (NDC: 00069-0344-01) is provided through the VFC Program in a 1-pack, 1-dose vial.
  - The minimum order quantity is 1 dose.
- ABRYSVO™ is recommended for pregnant people during 32 through 36 weeks gestation, using seasonal administration (Sept – January), to prevent RSV lower respiratory tract infection in infants.
- Given the small size of the eligible population and the recommended window for vaccination, the amount of vaccine available within the VFC program is modest. As a result, CDC has allocated doses to each state.

# 14 Days Remain! Submit your 2024 VFC Recertification!

- VFC Recertification Launched: **December 20, 2023**

-  • Due date: **Wednesday, January 31, 2024**

- Annual 2024 Recertification is completed through myVFCvaccines
  - Annual Recertification and Training **is a federal requirement** to maintain active status in the VFC Program and receive publicly purchased vaccines.
- All public and private providers must recertify yearly
  - Even if an LHD clinic is only receiving LHD 317 vaccine for outbreak or SGF vaccine
  - Recertification maintains the PIN's active status

# Recertification for LHD-317 and VFA Providers


- VFC Recertification in myVFCvaccines must be completed by 1/31/2024, prior to the transition to myCAvax in February 2024 in order to
  - Maintain PIN's active status in the VFC Program
  - Capture the primary VFA contact. This contact will receive all communications related to the myCAvax transition
- Part 2 of the LHD-317 and VFA Recertification process will be in myCAvax when those programs transition.
  - Update Key Practice Staff for the adult programs
  - The LHD-317 and VFA Provider of Record will sign the updated 2024 317 Provider Agreement or VFA Provider Agreement
    - The 317 and VFA Provider Agreements are not included in the VFC Recertification form so that the provider of record (POR) for the adult programs can sign these agreements in myCAvax.



# 2024-2025 VFC Flu Vaccine Pre-Book Coming Soon

VACCINES FOR CHILDREN (VFC) PROGRAM

## 3 PHASES OF VFC FLU ORDERING



- Pre-book will be available mid-to-late January and will be due February 2, 2024
- Prebooking is the first of three phases of the 2024-2025 VFC flu vaccine order process and will be the providers' ONLY chance to provide Flu Product brand preference AND the number of doses needed next season.
- More information will be communicated in the coming weeks, including a flu pre-book worksheet.

Anticipated 2024 VFC Flu products will include:

NDC	Flu Vaccine	Manufacturer	Description
70461-0654-03	Flucelvax	Seqirus (6 months - 18 years)	Inactivated, No Preservative, 0.5mL Single-Dose Syringe
19515-0810-52	FluLaval	GSK (6 months - 18 years)	Inactivated, No Preservative, 0.5mL Single-Dose Syringe
49281-0424-50	Fluzone	Sanofi (6 months - 18 years)	Inactivated, No Preservative, 0.5mL Single-Dose Syringe
66019-0311-10	Flumist	AstraZeneca (2 - 18 years)	Live Attenuated, No Preservative, 0.20mL Nasal Sprayer

# Vaccine Management

Josh Pocus, My Turn, and Claudia Aguiluz, myCAvax



## New updates for Patients launched on Tuesday, January 9, 2024!

### Release Highlights



#### Patients will be able to view:

- ✓ Postponed until 1/16 - The 'Single dose' and 'Both doses' options for the question 'Which appointment would you like to schedule for the mpox vaccine?' on the 'Walk-in' page
- ✓ Postponed until 1/16 - An updated copy for the question 'Which appointment would you like to schedule for the mpox vaccine?'
- ✓ Postponed until 1/16 - An updated copy on mpox tags on clinic cards on the 'Walk-in' page



# What's New in My Turn? – Release 47 (2 of 2)



## New updates for Clinic Managers and Vaccine Administrators launched on **Tuesday, January 9, 2024!**

### Release Highlights



#### Clinic Managers and Vaccine Administrators will be able to:

- ✓ CQE: Edit previously submitted records when the populated data is incorrect
- ✓ CQE: View all new records uploaded by other users from the same provider location but can only edit the records they have created
- ✓ CQE: View new dropdown options added to the 'Vaccine,' 'Vaccine Family,' 'Manufacturers,' and 'Package Information' fields on the CSV template
- ✓ My Turn Clinic: View new help text added to the 'Date of Birth,' 'Ethnicity,' 'Specify Race / Nationality,' 'Date Administered,' and 'Parent or Guardian's First Name' fields
- ✓ My Turn Clinic: Update and resubmit the appointment with the new products if the product selected during the appointment is an old flu product and was created on or after July 1, 2023



# California Immunization Registry (CAIR) Quick Entry



myCAVax  
California Vaccine Management System

Home Clinics Vaccine Inventory Appointments Enrollment IIS Status More

Welcome to My Turn Clinic

Need Help? Please see the Dashboards and Reports job aid and My Turn Interactive Guide.

Appointments by status

Completed appointments by vaccine

Completed pediatric appt (<18 yrs)

CAIR Quick Entry

View/Edit Records

Since the My Turn Release 46 on **Wednesday, December 20, 2023**, CAIR Quick Entry allows users to submit, view, and edit vaccine administration data for most vaccines to Immunization Information Systems (IIS).

## CAIR Quick Entry View & Edit Records

Records

1 items

Search Records

Location Name Clinic Name Status \*Submitted From \*Submitted To

Vaccine Family Manufacturer Name Vaccine DOB Last Name First Name

Search Reset

Record ID	Created Date	IIS Status	Location Name	Clinic Name	Vaccine Family	Manufacturer Name	Vaccine	Date Administered	First Name	Last Name	Date of Birth
66	Dec 12, 2023	Sample Locati...	Sample Clinic ...	Hepatitis A	GlaxoSmithKline	Heprix-Adult	Dec 11, 2023	James	Snow	Dec 1, 2005	

First Previous Next Last 1-1 of 1

# CAIR Quick Entry – Inline Submission



Users can inline upload vaccine administration data using CAIR Quick Entry (which may look similar to the existing inline upload process for vaccines in My Turn).

### CAIR Quick Entry Upload Records

**Inline Submission** CSV Submission

---

**Step 1**

Location Information

Location Name:  Clinic Name (optional):  IIS / CAIR ID:

> Optional: Pre-Populate Rows with Vaccine Information

**Step 2**

Patient information

Row	First name*	Last name*	Date of Birth*	Street Address*	City*	ZIP Code*	State*	Date Administered*	Vaccine Family*
<input type="button" value="trash"/> 1	<input type="text" value="James"/>	<input type="text" value="Snow"/>	<input type="text" value="12/1/20"/> <input type="button" value="calendar"/>	<input type="text" value="761 Angel Dr"/>	<input type="text" value="Monterey"/>	<input type="text" value="9..."/> <input type="button" value="calendar"/>	<input type="text" value="CA"/> <input type="button" value="dropdown"/>	<input type="text" value="12/12/20"/> <input type="button" value="calendar"/>	<input type="text" value="Hepatitis A"/> <input type="button" value="dropdown"/>

# CAIR Quick Entry – CSV\* Submission





CAIR Quick Entry Upload Records

Inline Submission **CSV Submission**

Upload your records with our CSV upload feature, following the instructions below.

1. Download [CSV template](#).
2. Input required information and export the file as UTF-8 CSV.
3. Choose your file below, then click "upload".

 **CSV Upload Requests**  
**Last 14 Days**

0 records • Refreshed at 9:49:14 AM 

First < Previous Next > Last

Request ID	Created Time	Submitted by	Status	Uploaded file	Success file	Error file
------------	--------------	--------------	--------	---------------	--------------	------------

First < Previous **Page 1 of 1** Next > Last

In addition to inline submission, users can upload vaccine administration data using CSV submission.



# CAIR Quick Entry – View / Edit Records (IIS Editing)



**Edit Record Fields**

**Location Information**

\* Location Name  
TLD Test Location 1

Clinic Name

**Vaccine Information**

\* Vaccine Family  
DENGUE

\* Vaccine  
DENGVAXIA

\* Lot Number  
DN1234

\* Injection Site  
Left Arm

\* Vaccine Administrator First Name  
VA

\* Manufacturer Name  
Sanofi Pasteur Inc.

\* Package Information  
VIAL / 0.5ML / SINGLE-DOSE

\* Route  
Intramuscular

\* Funding Source  
Private

\* Vaccine Administrator Last Name  
TLD

After submitting a record to IIS, you can edit select data, including Location and Vaccine Information.

# My Turn – Known Issues and Workarounds



## Known Issues

### CQE - Date Administered Discrepancy: Backend vs. Clinic Portal

- ✓ We fixed an issue where the Date Administered information on the backend did not match the date presented on the clinic portal.

### CQE - Funding Source Shown as 'Unknown' on the CAIR2 Side

- ✓ We have addressed an issue where the vaccines were documented in My Turn with the funding source as 'State General Funding.' However, CAIR2 read the funding source as 'Unknown.'



## Workaround / Next Steps

- ✓ Fixed: **January 9, 2024**

- ✓ Fixed: **January 9, 2024**

- ✓ My Turn accurately transmits 'State General Funding.' However, the term 'Unknown' in the CAIR2 portal was not sourced from My Turn and instead, linked to a particular lot number in the site's existing inventory, and the funding source information was not preserved when the lot inventory reached zero.

# Vaccines for Adults (VFA) and LHD 317 Providers: We are Moving!



The Vaccines for Adult Program (VFA) and the LHD 317 Program will be moving into myCAVax next month!

myCAVax functionality to support ordering and vaccine management for these programs is expected to be included in the **February 20, 2024**, release.

CDPH will soon be sharing detailed steps on the transition and important steps **you need to take** to prepare.

Provider and LHD system training will begin in late January/Early February. Dates and registration links will be shared in the coming weeks. Stay tuned!

# Vaccines for Adults (VFA) and LHD 317 Providers: We are Moving!



Please make sure your site **completes VFC's Recertification by January 31, 2024**, and CONFIRM the VFA or LHD 317 Vaccine Coordinator contact information!

The VFA or LHD 317 Contact will receive all notifications about the system transition to myCAVax, with more details about recertifying and signing participation Agreements and Addendums in myCAVax. The VFA or 317 LHD contact information will be the only key practice staff migrated to myCAVax.

These contacts will be displayed as the Primary Vaccine Coordinator.

# Reminder: New Refrigerated Pfizer COVID-19 Vaccine for 12y+



The previous Pfizer 12y+ vaccine allocations have been replaced with Pfizer's new refrigerated 12y+ vaccine (NDC 00069-2377-10), a new presentation in a carton of 10 manufacturer-filled syringes (MFS).

Providers who have the original Pfizer 12y+ vaccine on hand can and should continue to use this product until it is consumed, expired, or has been stored at 2–8 °C for longer than the allowable 10 weeks.

**Important:** There are no temperature monitors being shipped with this product. Shipments maintain temperatures for 84 hrs. **Please check the shipment's date (on the outside shipment label)** to ensure it is received within this timeframe.

# McKesson COVID-19 Vaccine Shipping Update



Beginning this week, McKesson will temporarily be using one of two different warm temperature monitors for vaccine shipments. Coolers may contain the familiar 3M monitor or may contain a new monitor, SpotSee.

This temporary change in temperature monitors will be in place until approximately Feb 1 when a new and improved temperature monitor will be used for refrigerated shipments. See [Supplemental Resource on Temporary Loggers](#), Provided by McKesson for additional support.

Both the 3M monitor and SpotSee monitor are one-time use only and should be disposed of once the vaccine has been properly stored.


Please follow the same process for checking for any temperature excursions and follow the directions on the information card specific to the monitor received.

## How to Read the WarmMark® Temperature Indicator

As soon as you receive this shipment, remove the WarmMark® Temperature Indicator and check the Index. Please note that all pictures below are examples only. Please read the monitor on the other side of this card.

### For all vaccines excluding MMR:

- If the Index color is MODERATE, store the vaccines as instructed and begin use.
- If the Index color is PROLONGED, store the vaccines as instructed and call 877-TEMP123 (877-836-7123) or your state / local immunization program right away for further instruction before using.



### For MMR vaccines only:

- If the Index color is BRIEF, store the vaccines as instructed and begin use.
- If the Index color is MODERATE or PROLONGED, store the vaccines as instructed and call 877-TEMP123 (877-836-7123) or your state / local immunization program right away for further instruction before using.



## WarmMark® Time Temperature Indicator decision table:

Indicator Color	Vaccine Type	
	Vaccines (excluding MMR)	MMR
BRIEF	Ready for Use	
MODERATE	Ready for Use	Call 877-TEMP123 (877-836-7123) or your state / local immunization program <u>right away</u>
PROLONGED	Call 877-TEMP123 (877-836-7123) or your state / local immunization program <u>right away</u>	

Call 877-TEMP123 (877-836-7123) or your state / local immunization program right away if you have questions or concerns when reading the temperature indicator or if you see damage to the package.



# January BAP Holiday Shipping Cadence

## January Holiday Ordering & Distribution Cadence Calendar

California BAP COVID-19 Vaccination Program (Providers/LHDs)

Monday	Tuesday	Wednesday	Thursday	Friday
January 01	02	03	04	05
Holiday Hold – No Vaccine Deliveries	Provider Order (submit by 3PM)	LHD Approval by 12PM		
		CDPH Transmits to CDC		
	Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer			
08	09	10	11	12
Provider Order (submit by 5PM)		LHD Approval by 12PM		
		CDPH Transmits to CDC		
	Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer			
15	16	17	18	19
Provider Order (submit by 3PM)		LHD Approval by 12PM		
Holiday Hold – No Vaccine Deliveries		CDPH Transmits to CDC		
	Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer			



- Delivery windows are dependent on provider's days/hours of operation. Shipments will be sent the following week of order approval and processing. [\*\* Adjusted Delivery date due to Holiday]
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.



# January SGF Holiday Shipping Cadence

## January Holiday Ordering & Distribution Cadence Calendar




California SGF Flu Vaccination Program (Providers/LHDs)

Monday	Tuesday	Wednesday	Thursday	Friday
January 01	02	03	04	05
	LHD Approval by 12PM			LHD Approval by 12PM
	CDPH Transmits to CDC			CDPH Transmits to CDC
<b>Holiday Hold – No Vaccine Deliveries</b>	Flu Vaccine Delivery – McKesson Direct Ship			
		Provider Order (submit by 5PM)		Provider Order (submit by 5PM)
08	09	10	11	12
	LHD Approval by 12PM			LHD Approval by 12PM
	CDPH Transmits to CDC			CDPH Transmits to CDC
	Flu Vaccine Delivery – McKesson Direct Ship			
		Provider Order (submit by 5PM)		Provider Order (submit by 5PM)
15	16	17	18	19
	LHD Approval by 12PM			LHD Approval by 12PM
	CDPH Transmits to CDC			CDPH Transmits to CDC
<b>Holiday Hold – No Vaccine Deliveries</b>	Flu Vaccine Delivery – McKesson Direct Ship			
		Provider Order (submit by 5PM)		Provider Order (submit by 5PM)



- Delivery windows are dependent on provider's days/hours of operation. Shipments will be sent the following week of order approval and processing. [\*\* Adjusted Delivery date due to Holiday]
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

# Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

# myCAvax – Known Issues and Workarounds



## Known Issues

### Transfer and Order Related List Views Tied Together

- ✓ We will be correcting a visibility issue in which Sending Transfers are only visible on a Vaccine Order's related list views when looking at an Account or Program Location. While Receiving Transfers have their own unique related list view, Sending Transfers should also have their own unique related list view.

### Some Sending Transfers Missing from Program Related List Views

- ✓ We will be correcting an issue in which some Sending Transfers are not showing in their respective Program Location's related list views but are still visible from their Account's related list views – for now, the Account should be taken as the source of truth if you notice a mismatch.



## Workaround / Next Steps

- ✓ Estimated Fix: **February 2024**

- ✓ Estimated Fix: **February 2024**

# Resources and Q&A

Leslie Amani and CDPH SMEs

# EZIZ.ORG

- Home
- Vaccine Programs
- Vaccine Management
- Storage Units
- Temperature Monitoring
- Training & Webinars**
- Clinic Resources
- Patient Resources

**EZIZ**  
A one-stop shop for immunization training and resources.

ENHANCED BY Google

### California's Vaccine Programs

- VFC** California Vaccines for Children Program
- VFA** California Vaccines for Adults Program
- BAP** California Bridge Access Program
- 317** Local Health Departments

### Ordering & Vaccine Management

- MyVFCvaccines (for VFC and VFA)
- VFC Holiday Ordering Calendar
- MyCAvax (for BAP and 317)

### Storage Requirements

- Vaccine Storage Units
- Digital Data Loggers

### Alerts!

**2023-24 COVID-19 Vaccine**

- COVID-19 Vaccine Resources: For Providers | For Patients
- Vaccine Ordering and Manufacturer Info

**Protect your patients against RSV!**

- RSV Immunization FAQs
- Resources for Providers and Patients

**Holiday Ordering & Distribution Cadence Calendars**

- CA BAP COVID-19 Vaccine Program – Holiday Ordering & Distribution Calendar
- CA SGF Flu Vaccination Program – Holiday Ordering & Distribution Calendar

**New/Updated Materials**

- Vaccines for 65+ poster: English | Spanish
- Vaccines for Pregnant Women flyer: English | Spanish
- Brochure: English | Spanish
- Fall-Winter 2023 Immunizations Infographic | Spanish

### Hot Topics

**Weekly CDPH Immunization Updates for Providers**

- Immunization Registry Requirements
- COVID-19 Vaccine Resources

### Popular Resources

- For Patients and Staff
- Flu
- Mpox
- Pertussis
- Schedules & Recommendations
- VFC Vaccine Fact Sheets
- For Pharmacies

### CDPH Applications

- My Turn** (COVID/Flu Vaccine Administration System)
- CAIR** (California Immunization Registry)
- My DVR** (Digital Vaccine Records)
- CAIR-ME** (Medical Exemptions from Immunizations for School and Child Care)



ENHANCED BY Google

*A one-stop shop for immunization training and resources.*

**Home**

Vaccine Programs

Vaccine Management

Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources

---

**Contact VFC**

Phone: (877) 243-8832  
Hours:  
Mon-Thurs, 9AM-4:30PM  
Friday, 9AM-4PM  
Send us an email  
Fax: (877) 329-9832

- ▶ VFC Field Representatives
- ▶ Find VFC providers
- ▶ Sign up for EZIZ emails
- ▶ Frequently Asked Questions

**California's Vaccine Programs**

 <b>VFC</b> <small>California Vaccines for Children Program</small>	<b>VFA</b> <small>California Vaccines for Adults Program</small>	<b>BAP</b> <small>California Bridge Access Program</small>	<b>317</b> <small>Local Health Departments</small>
---	---	---	---

**Ordering & Vaccine Management**

**Storage Requirements**

<ul style="list-style-type: none"> <li>• MyVFCvaccines (for VFC and VFA)</li> <li>• MyCAvax (for BAP and 317)</li> </ul>	<ul style="list-style-type: none"> <li>• Vaccine Storage Units</li> <li>• Digital Data Loggers</li> </ul>
--	---

**Alerts!**

**2023-24 COVID-19 Vaccine**

- COVID-19 Vaccine Resources: For Providers | For Patients
- Vaccine Ordering and Manufacturer Info

**Protect your patients against RSV!**

- RSV Immunization FAQs
- Resources for Providers and Patients

**Holiday Ordering & Distribution Cadence Calendars**

- VFC Program
- CA BAP COVID-19 Vaccine Program
- CA SGF Flu Vaccination Program

VFC Memos

Vaccine Order Status

From CDPH

**Hot Topics**

**Weekly CDPH  
Immunization  
Updates for Providers**

- Immunization Registry Requirements
- COVID-19 Vaccine Resources

**Popular Resources**

- ▶ For Patients and Staff
- ▶ Flu
- ▶ Mpox
- ▶ Pertussis
- ▶ Schedules & Recommendations
- ▶ VFC Vaccine Fact Sheets
- ▶ For Pharmacies

**CDPH Applications**

- ▶ **My Turn** (COVID/Flu Vaccine Administration System)
- ▶ **CAIR** (California Immunization Registry)
- ▶ **My DVR** (Digital Vaccine Records)
- ▶ **CAIR-ME** (Medical Exemptions from Immunizations for School and Child Care)

**COVID-19 Vaccine Resources**

This landing page provides vaccine-specific resources to support all programs that supply COVID-19 vaccines.

**Jump To Topic:**

- Vaccine Information
- Clinical Resources
- Vaccine Administration
- Communicating with Patients
- Archived Communications

**Vaccine Information**

- Required Vaccine Product Training (CDC)
- COVID-19 Vaccine Fact Sheets (CDPH)
- COVID-19 Vaccine Product Guide
- COVID-19 Vaccine Timing Guide | Spanish
- Vaccine Program Eligibility Guidelines: VFC, VFA, BAP (for Community Health Centers)
- Vaccine Ordering & Manufacturer Info (private and public vaccines)
- COVID-19 Provider FAQs (Updated 12/14)
- COVID-19 Vaccine Product Information Guide (CDC, not yet updated for 2023)
- Receiving & Storage Vaccine Shipments

**Pediatric Vaccine Resources**

- COVID-19 is a Childhood Illness (CDPH)
- 6 Things to Know about COVID-19 Vaccination for Children (CDC)
- Equity in Childhood COVID-19 Vaccination (CDC)

**Vaccine Information Statements (VISs)**

Currently, providers are required by law to provide EUA fact sheets to vaccine recipients or their caregivers for all uses of Novavax and when Moderna or Pfizer vaccines are given to children 6 months through 11 years of age. For recipients who are 12 or older receiving Pfizer or Moderna vaccine, a provider may use the COVID-19 Vaccine Information Statement (VIS). See [CDC Vaccine Information Statements](#).

**Pfizer-BioNTech (2023-24 COVID-19 Vaccine, mRNA)**

- Pfizer at a Glance (CDC)
- Pfizer Storage and BUD Label
- Approval of Comirnaty for 12Y+: Provider Letter | Package Insert | COMIRNATY (FDA)

# Provider Operations Manual

## California Bridge Access Program

### Special Note for Providers

You played a critical role in helping to end the COVID-19 pandemic.

For patients, you are one of the most trusted sources of information when it comes to vaccines. Patients may have questions and concerns about COVID-19 vaccines. You can help them understand the importance of vaccination, provide your strong recommendation, and build confidence in vaccines.

Strong vaccine confidence leads to more people getting vaccinated, which leads to fewer COVID-19 illnesses, hospitalizations, and deaths.

Thank you for the efforts you and your practice staff are making to keep California healthy.



California Bridge Access Program

## Provider Operations Manual

no-cost  
COVID-19 vaccines

thank  
you

for uninsured &  
underinsured adults



Click to Navigate  
Table of Contents

Startup Guide

Appendices  
Important contacts

Infrequent Tasks  
Introduce new vaccines, change staff or contacts, set up new storage unit, and data logger

<b>1</b> <b>Ordering Vaccines</b> About vaccine orders Vaccine products Submitting vaccine order requests Minimizing shipment delays When to expect vaccines	<b>2</b> <b>Receiving &amp; Storing Vaccine Shipments</b> About receiving shipments Moderna Novavax Pfizer-BioNTech Reporting shipment incidents	<b>3</b> <b>Routine Tasks &amp; Reporting</b> Recurring tasks & frequency Reporting requirements	<b>4</b> <b>Managing Vaccine Inventory</b> Inventory management checklist Monitoring temperatures Reporting temperature excursions Expiration & beyond-use dates Wastage & missed opportunities Reporting & return of nonviable doses Transporting vaccines Transferring vaccine	<b>5</b> <b>Patient Visit</b> Patient visit checklist Eligibility Screening & Documentation How to Screen & Document Eligibility Vaccine preparation & administration Responding to administration errors Billing & Reimbursement
--	--	---	---	--



# COVID-19 Vaccine and Therapeutics FAQs

## Answers to providers' COVID-19 vaccine and therapeutics questions!

Updated Thursday, January 11, 2024

Updated

**Q: *Where can I find information about COVID-19 vaccination and pregnancy?***

A: COVID-19 vaccination [is recommended](#) for people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. For patient resources, please refer to [CDPH Pregnancy and Immunizations Toolkit](#).

Updated

**Q: *Is there a refrigerated presentation of COVID-19 vaccine?***

A: Yes. There is a new refrigerated Pfizer 12y+ COVID-19 vaccine. This new presentation comes as single-dose pre-filled syringes and must be stored between 2°C - 8°C (36°F and 46°F). For more information and resources, please refer to this [CDPH communication](#), the updated [COVID-19 Vaccine Adolescent/Adult \(12Y+\) fact sheet](#), and the updated [COVID-19 Vaccine Product Guide](#).

COVID-19 Vaccine and Therapeutics FAQs v.138\_01.11.24 1

### COVID-19 Vaccine and Therapeutics FAQs

For providers administering COVID-19 vaccine, and treating COVID-19. Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

<a href="#">New and Updated FAQs</a>	2
<a href="#">COVID-19 Vaccine Access</a>	2
<a href="#">Bridge Access Program (BAP)</a>	4
<a href="#">Vaccine Administration</a>	8
<a href="#">Vaccine Storage &amp; Handling</a>	10
<a href="#">Reporting</a>	11
<a href="#">Therapeutics</a>	13
<a href="#">Communication Resources</a>	14

# CDPH Provider Webinars and Trainings



## Week of January 15, 2024

	Monday 1/15	Tuesday 1/16	Wednesday 1/17	Thursday 1/18	Friday 1/19
12 Live Webinars and Training					<a href="#">CDPH Immunization Updates for Providers</a> 9:00 am – 10:30 am
View On Demand	<ul style="list-style-type: none"> <li><a href="#">CDPH Weekly Provider Archived Webinars and Slides</a></li> <li><a href="#">COVID-19 Crucial Conversations Archived Webinars and Slides</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>		<ul style="list-style-type: none"> <li><a href="#">Introduction to My Turn Onboarding (v. 1/4/22)</a></li> <li><a href="#">Latest Features in My Turn (Requires myCAvax Login)</a></li> <li><a href="#">myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)</a></li> </ul>		<ul style="list-style-type: none"> <li><a href="#">Moderna COVID-19 Vaccine Resources for Providers</a></li> <li><a href="#">CDC COVID-19 Vaccination Clinical &amp; Professional Resources</a></li> <li><a href="#">Novavax COVID-19 Vaccine Information</a></li> <li><a href="#">Pfizer COVID-19 Vaccine (COMIRNATY) Information</a></li> </ul>

<b>Help</b>	<b>Help Desk</b>	<b>Immunization Resources</b>
	<p>*CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a></p> <p>My Turn: Help Desk Email: <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a> Onboarding Email: <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a></p> <p>myCAvax: Help Desk Email: <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a> Mpox: Email: <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a></p> <p>COVID-19 Treatments: Warmline for LTCF/SNF staff: 1-866-268-4322, M-F 8am-5pm, <a href="#">Test to Treat Help Form</a></p>	<p><a href="#">California's General Immunization Resources (eziz.org)</a></p> <p><a href="#">RSV Immunization Resources</a>      <a href="#">Flu Vaccination Resources</a></p> <p><a href="#">COVID-19 Vaccination Resources</a>      <a href="#">COVID-19 Treatments</a></p> <p><a href="#">Mpox Vaccination Resources</a></p>


# Vaccine Support


## Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: [myCAvax.hd@cdph.ca.gov](mailto:myCAvax.hd@cdph.ca.gov)
- For My Turn Clinic Help Desk inquiries: [MyTurn.Clinic.HD@cdph.ca.gov](mailto:MyTurn.Clinic.HD@cdph.ca.gov)
- For all other inquiries: [providercallcenter@cdph.ca.gov](mailto:providercallcenter@cdph.ca.gov)
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

## myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our jobs aids in the Knowledge Center, or contact us.



# COVID-19 Therapeutics Resources

## Type of Support

## Description

Updated 11.27.23



### Clinical Guidance

For general Therapeutics questions, please email: [COVIDRxProviders@cdph.ca.gov](mailto:COVIDRxProviders@cdph.ca.gov)  
COVID-19 Treatment Warmline for SNF and LTCF staff: 1.866.268.4322 M-F 8am-5pm



### General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)  
[CDPH COVID-19 Treatments Job Aid](#) (questions and answers for the public on COVID-19 therapeutics)  
[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more)  
[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



### Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (arcgis.com)
- [Test-to-Treat](#) (hhs.gov)



### LHJ Therapeutics SharePoint

Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email [JEOCuser54@cdph.ca.gov](mailto:JEOCuser54@cdph.ca.gov))

- [Therapeutic Weekly Email Update](#) files (SharePoint)
- [CDPH Therapeutics HPOP Account Verification & Reporting](#) information




### Questions

For general CDPH Therapeutics questions, please email [COVIDRxProviders@cdph.ca.gov](mailto:COVIDRxProviders@cdph.ca.gov)  
For ordering, program inquiries, signing up new HPOP Accounts: please e-mail [CDPHTherapeutics@cdph.ca.gov](mailto:CDPHTherapeutics@cdph.ca.gov)

# Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, "Chat"



# Upcoming Webinar Opportunities

## CDPH Immunization Updates for Providers

**Next session: Friday, January 19, 2024**

**9AM – 10:30AM**

